Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Imatinib Mesylate in Treating Patients With Recurrent or Metastatic Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed non-small cell cancer~  * Recurrent disease after adjuvant treatment OR progressive disease after 1 prior treatment for recurrent or metastatic disease~* Received at least 1 prior chemotherapy regimen and meets the following criteria:~  * No more than 1 prior chemotherapeutic regimen in the recurrent or metastatic setting~ * Patients who received prior chemotherapy in the adjuvant setting are eligible when 1 of the following criteria is met:~    * In first recurrence (after 1 prior regimen)~   * Received first-line chemotherapy in the recurrent setting after 2 prior regimens~* Measurable disease~  * Must have ≥ 1 measurable target lesion outside prior radiotherapy field OR radiologic confirmation of disease progression within a prior radiotherapy field~* No known or untreated brain metastases or carcinomatous meningitis~  * Clinically stable, treated brain metastases allowed provided it has been \> 7 days since prior steroids~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Life expectancy ≥ 3 months~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Bilirubin ≤ 1.5 times upper limit of normal (ULN)~* AST and ALT ≤ 2.5 times ULN~* Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 3 months after completion of study treatment~* Able to swallow oral medication~* No concurrent medical condition that would preclude study compliance~* No history of allergic reaction to compounds of similar chemical or biological composition to gemcitabine hydrochloride or imatinib mesylate~* No uncontrolled illness that would preclude study compliance, including any of the following:~  * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia requiring therapy~ * Myocardial infarction within the past 6 months~ * Active infection~* No New York Heart Association class III-IV congestive heart failure~* No chronic liver disease (i.e., chronic active hepatitis, cirrhosis)~* No HIV positivity~* No other primary malignancies within the past 5 years, except carcinoma in situ of the cervix or nonmelanoma skin cancer~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas)~* At least 3 weeks since prior anti-vascular endothelial growth factor therapy and recovered~* At least 3 weeks since prior radiotherapy and recovered~* More than 28 days since prior and no other concurrent investigational or commercial agents~* More than 2 weeks since prior major surgery~* No prior gemcitabine hydrochloride or imatinib mesylate for metastatic disease~* No prior tyrosine kinase inhibitor, except for gefitinib or erlotinib hydrochloride~* No concurrent therapeutic warfarin (prophylactic warfarin therapy ≤ 1 mg daily allowed)~* No other concurrent medications that would preclude study compliance~* No concurrent chronic systemic corticosteroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine hydrochloride and imatinib mesylate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues